Zydus Lifesciences informs about press release

06 Nov 2025 Evaluate
Zydus Lifesciences has informed that it enclosed a copy of press release dated November 6, 2025, titled ‘Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of betathalassemia’.

The above information is a part of company’s filings submitted to BSE.  

Zydus Lifesciences Share Price

911.50 -5.95 (-0.65%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×